Nebenwirkungen · Lokelma
Lokelma 5 g powder for oral suspension Lokelma 10 g powder for oral suspension · Abschnitt 4.8 · PDF-Seite 6
HOS-133823 · Präparat HOS-097504
Oedema related events, including fluid retention, generalised oedema, hypervolaemia, localised oedema, oedema, oedema peripheral and peripheral swelling, were reported by 5.7% of Lokelma patients. The events were observed in the maintenance phase only and were more commonly seen in patients treated with 15 g. Up to 53% were managed by initiating a diuretic or adjusting a diuretic dose; the remainder did not require treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-02T16:15:00Z · SHA-256 9a57e63114421578bcab7ac6769b720be4b42c5e469c19bbe95a69fe93e5ab56 · Passage 1b811ad2c05104c323e891267a3e0a2cc0a086f6afb3152b92daf1c7e8f82000 · Zeichen 2932–3361 im Abschnitt